a glucagon triple-receptor agonist in early stage clinical development for obesity, Type 2 diabetes and other diseases. Novo Nordisk will acquire the rights to develop, manufacture and ...

Medically reviewed by Suzanne Fisher, RD Hypoglycemia (low blood sugar) treatments will depend on the severity of symptoms ...

“Of central importance for a novel T2D drug is that it targets the key islet dysfunctions that underlie hyperglycaemia — that is, impaired insulin secretion, inappropriately high glucagon ...